Download App

Log in to access Online Inquiry
Company Overview More
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
CEO: Lin M.B.A., Ph.D., Yu-Hsin
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > BLTE Belite Bio > Detailed Quotes

BLTE Belite Bio

12.330-1.070-7.99%
Close 05/18 20:00 ET
High
13.480
Open
13.230
Turnover
2.23M
Low
11.960
Pre Close
13.400
Volume
175.09K
Market Cap
297.10M
P/E(TTM)
Loss
52wk High
17.500
Shares
24.10M
P/E(Static)
Loss
52wk Low
8.800
Float Cap
73.98M
Bid/Ask %
-16.67%
Historical High
17.500
Shs Float
6.00M
Volume Ratio
1.25
Historical Low
8.800
Dividend TTM
--
Div Yield TTM
--
P/B
-19.70
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
2.92%
Amplitude
11.34%
Avg Price
12.737
Lot Size
1
Float Cap
73.98M
Bid/Ask %
-16.67%
Historical High
17.500
Shs Float
6.00M
Volume Ratio
1.25
Historical Low
8.800
Dividend TTM
--
P/B
-19.70
Dividend LFY
--
Turnover Ratio
2.92%
Amplitude
11.34%
Avg Price
12.737
Lot Size
1
Price Forecast

No Data

News

Comment